<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423459</url>
  </required_header>
  <id_info>
    <org_study_id>EPROMPT</org_study_id>
    <nct_id>NCT03423459</nct_id>
  </id_info>
  <brief_title>CoreValve Evolut Pro Prospective Registry</brief_title>
  <official_title>CoreValve Evolut Pro Prospective Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the real-world performance of the&#xD;
      CoreValve Evolut PRO transcatheter aortic valve, including leaflet function, in a prospective&#xD;
      observational registry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CoreValve Evolut PRO transcatheter aortic valve was approved by the FDA in March 2017 to&#xD;
      treat patients with symptomatic severe aortic stenosis at high or extreme risk for open heart&#xD;
      surgery, and in July 2017 for intermediate risk patients. This latest generation device&#xD;
      features an outer wrap to improve annular sealing and reduce paravalvular leak.&#xD;
&#xD;
      In this observational study, baseline demographic and imaging characteristics, procedural&#xD;
      details and clinical outcomes of patients undergoing transcatheter aortic valve replacement&#xD;
      with the CoreValve Evolut PRO will be prospectively collected into a registry database. The&#xD;
      institutional Heart Team will select patients according to standard practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Device success:</measure>
    <time_frame>30 days</time_frame>
    <description>Absence of procedural mortality Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient&lt;20 mm Hg or peak velocity&lt;3 m/s, AND no moderate or severe prosthetic valve regurgitation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>all causes of death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Stroke (disabling and non-disabling</measure>
    <time_frame>30 days</time_frame>
    <description>Stroke will evaluated using the VARC-2 definition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Life Threatening Bleeding</measure>
    <time_frame>30 Days</time_frame>
    <description>Life Threatening Bleeding will be evaluated using the VARC-2 definition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute Kidney Injury Stage 2 or 3</measure>
    <time_frame>30 days</time_frame>
    <description>AKI will be evaluated using the VARC-2 definition of Stage 2 or 3 AKI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary Artery Obstruction requiring intervention</measure>
    <time_frame>30 days</time_frame>
    <description>This will be assessed if by noting whether the patient has a re intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Vascular Complication</measure>
    <time_frame>30 days</time_frame>
    <description>Major Vascular Complication will be evaluated using the VARC-2 definition of Major Vascular Complication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Valve - related Dysfunction</measure>
    <time_frame>30 Days</time_frame>
    <description>Valve related dysfunction will be evaluated by determining whether the subject has a repeat procedure such as a BAV, TAVI, or SAVR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prosthetic valve dysfunction #1</measure>
    <time_frame>1 year</time_frame>
    <description>Mean aortic valve gradient ≥20 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthetic valve dysfunction #2</measure>
    <time_frame>1 year</time_frame>
    <description>Moderate-severe transvalvular aortic regurgitation as determined by the echo core lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthetic valve dysfunction #3</measure>
    <time_frame>1 year</time_frame>
    <description>Abnormal leaflet thickening on CT as determined by the CT Core lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthetic valve dysfunction #4</measure>
    <time_frame>1 year</time_frame>
    <description>Decreased leaflet mobility on CT as determined by the CT Core lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prosthetic valve dysfunction</measure>
    <time_frame>1 year</time_frame>
    <description>Leaflet thrombosis on CT as determined by the CT Core lab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in PVL</measure>
    <time_frame>Discharge thru to 1 year</time_frame>
    <description>This will be evaluated by echo core lab findings</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>CT Cohort</arm_group_label>
    <description>Compare the rate of ≥mild PVL in patients with none/mild versus moderate/severe LVOT calcification.&#xD;
Comparison of the rate of PPM implantation in patients with none/mild versus moderate/severe LVOT calcification.&#xD;
Determine how the Evolut PRO conforms to LVOT calcification.&#xD;
Compare the impact of LVOT calcification on the implantation depth of the Evolut PRO.&#xD;
Analyze the interaction and geometry of the Evolut PRO in patients with moderate/severe LVOT calcification.&#xD;
Assess for leaflet thickening, subclinical leaflet thrombosis and/or restricted leaflet motion 30-60 days after TAVR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-CT Cohort</arm_group_label>
    <description>Compare the rate of ≥mild PVL with the Evolut PRO with a propensity score matched cohort of historical control subjects who underwent TAVR with the Evolut R and/or CoreValve within the MedStar Health System.&#xD;
Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict ≥mild PVL.&#xD;
Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict PPM implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVR</intervention_name>
    <description>Transcatheter Aortic Valve Replacement</description>
    <arm_group_label>CT Cohort</arm_group_label>
    <arm_group_label>Non-CT Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study is a prospective registry of subjects with symptomatic severe aortic stenosis&#xD;
        undergoing TAVR with a commercially-approved self-expanding transcatheter heart valve. A&#xD;
        subgroup of subjects will undergo additional research contrast-enhanced 4D CT at 30-60 days&#xD;
        after TAVR. Otherwise, all additional test and TAVR implantation procedures are as per&#xD;
        standard of care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic severe aortic stenosis&#xD;
&#xD;
          2. Intermediate, high or extreme surgical risk&#xD;
&#xD;
          3. The institutional Heart Team determines that transcatheter aortic valve replacement&#xD;
             with an Evolut Pro device is appropriate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject unable or unwilling to give informed consent&#xD;
&#xD;
          2. For subjects in the CT arm only, renal function precluding the administration of&#xD;
             iodinated contrast for cardiac CT (eGFR &lt; 30 ml/min/1.73m2). An exception to this&#xD;
             exclusion criterion is made if the subject is established on renal replacement therapy&#xD;
             and is therefore able to receive intravenous iodinated contrast media.&#xD;
&#xD;
          3. Pregnancy or intent to become pregnant prior to completion of all protocol follow-up&#xD;
             procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Megan Rowland, MPH</last_name>
    <phone>202-877-2959</phone>
    <email>megan.e.rowland@medstar.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Rowland, MPH</last_name>
      <phone>202-877-2959</phone>
      <email>megan.e.rowland@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Ron Waksman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medstar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Wang</last_name>
      <phone>410-554-2332</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

